A phase IV prospective randomized open-label single-center study of pulse wave velocity evaluation tacrolimus time in therapeutic range and co-efficient of tacrolimus variation of African American kidney transplant recipients receiving immediate release tacrolimus capsules (IR-Tac) or extended release tacrolimus tablets (LCPT)
Enrolling By Invitation
99 years or below
All
Phase
4
60 participants needed
1 Location
Brief description of study
The primary purpose of this study is to evaluate the pulse wave velocity and vascular compliance measurements at the beginning and the end of the study while the patient is taking either Envarsus XR® (extended release tacrolimus) tablets administered once-daily after transplantation or immediate release generic tacrolimus capsules that are administered twice-daily after kidney transplantation. Pulse wave velocity and vascular compliance measurements are two non-invasive tests that are used to evaluate how well patients blood vessels adapt to each heartbeat. The secondary purpose is to look at the effectiveness and safety of extended release tacrolimus tablets administered once-daily compared to generic tacrolimus capsules administered twice-daily after kidney transplantation.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Kidney Transplant; Complications
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 832046
If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu
